Crossmark

Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Crossref DOI link: https://doi.org/10.1007/s40121-023-00806-0

Published Online: 2023-05-11

Published Print: 2023-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Choi, Yu Hwa

Kang, Young Ae

Park, Kwang Joo

Choi, Jae Chol

Cho, Kwan Goo

Ko, Da Yeon

Ahn, Jun Ho

Lee, Boram

Ahn, Eunsol

Woo, Yun Ju

Jung, Kwangsoo

Kim, Nan Yul

Reese, Valerie A.

Larsen, Sasha E.

Baldwin, Susan L.

Reed, Steven G.

Coler, Rhea N.

Lee, Hyejon http://orcid.org/0000-0001-8207-537X
Cho, Sang-Nae
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03806686 at ClinicalTrials.gov

Documents that mention this clinical trial

Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
https://doi.org/10.1007/s40121-023-00806-0
License Information

Text and Data Mining valid from 2023-05-11

Version of Record valid from 2023-05-11
More Information

Article History

Received: 7 February 2023

Accepted: 11 April 2023

First Online: 11 May 2023

Document is current

Any future updates will be listed below